Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia - Overview
Critical Limb Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Critical Limb Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Critical Limb Ischemia - Companies Involved in Therapeutics Development
Critical Limb Ischemia - Drug Profiles
Critical Limb Ischemia - Dormant Projects
Critical Limb Ischemia - Discontinued Products
Critical Limb Ischemia - Product Development Milestones
Featured News & Press Releases
May 10, 2022: Hemostemix announces its intellectual property is back home
Mar 24, 2022: Hemostemix announces settlement agreement
Sep 08, 2021: Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001
Jul 06, 2021: Hemostemix provides update of Phase II clinical trial, 9th Circuit Court Decision including Cost Award and its Annual General Meeting Results
Apr 23, 2021: Hemostemix announces completion of phase II clinical trial subject follow up & HMTXF Up-list
Mar 18, 2021: Hemostemix announces clinical trial update and contract with Globex data to encrypt its communications with regulatory authorities
Jan 28, 2021: Hemostemix announces HS 12 - 01 clinical trial completion of subjects’ follow-up visits at the end of march and warrants extented and repriced
Oct 26, 2020: Rexgenero announces positive outcome of independent data monitoring committee meeting for phase III trial for diabetic patients with critical limb-threatening ischaemia
Sep 09, 2020: Caladrius Biosciences announces registration of HONEDRA trademark and new patent in Japan
Jul 06, 2020: Aspire Health Science, announces release of ACP-01 midpoint alysis to Hemostemix
Apr 01, 2020: Cyta provides guidance on planned CLI clinical trial
Mar 03, 2020: Cadian patent issued for Cyta Therapeutics unique stem cell technology
Jan 26, 2020: Hemostemix provides corporate update and clarification
Jan 14, 2020: UK regulatory authority approves Cyta’s phase 2 clinical trial in critical limb ischaemia
Nov 25, 2019: Cyta files application to commence phase 2 clinical trial in critical limb ischaemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Critical Limb Ischemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Critical Limb Ischemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Critical Limb Ischemia - Dormant Projects, 2022
Critical Limb Ischemia - Dormant Projects, 2022 (Contd..1)
Critical Limb Ischemia - Dormant Projects, 2022 (Contd..2)
Critical Limb Ischemia - Discontinued Products, 2022